{"id":"tremelimumab-regimen-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Immune-related colitis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Pneumonitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Tremelimumab binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a checkpoint protein that normally suppresses T cell activation. By blocking CTLA-4, the antibody prevents tumor cells from turning off immune responses, allowing T cells to proliferate and attack cancer cells more effectively. This mechanism is particularly potent when combined with other immunotherapies such as PD-L1 inhibitors.","oneSentence":"Tremelimumab is a monoclonal antibody that blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:09.285Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unresectable or metastatic melanoma (in combination with durvalumab)"},{"name":"Hepatocellular carcinoma (in combination with durvalumab)"}]},"trialDetails":[{"nctId":"NCT07489976","phase":"PHASE2","title":"IIT2025-03-YANG-LIFT-HCC","status":"RECRUITING","sponsor":"Ju Dong Yang","startDate":"2026-04-01","conditions":"Hepato Cellular Carcinoma","enrollment":41},{"nctId":"NCT03298451","phase":"PHASE3","title":"Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-10-11","conditions":"Hepatocellular Carcinoma","enrollment":1324},{"nctId":"NCT07175441","phase":"PHASE2","title":"Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Riboscience, LLC.","startDate":"2026-04","conditions":"Advanced Unresectable Hepatocellular Carcinoma","enrollment":220},{"nctId":"NCT06608940","phase":"PHASE1, PHASE2","title":"BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma","status":"WITHDRAWN","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-11","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":""},{"nctId":"NCT06904170","phase":"PHASE2, PHASE3","title":"Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-11-14","conditions":"Hepatocellular Carcinoma","enrollment":196},{"nctId":"NCT06008093","phase":"PHASE3","title":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-04-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":280},{"nctId":"NCT02571725","phase":"PHASE1, PHASE2","title":"PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"New Mexico Cancer Research Alliance","startDate":"2016-02-23","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms","enrollment":50},{"nctId":"NCT03601455","phase":"PHASE2","title":"Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2018-10-26","conditions":"Bladder Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8","enrollment":13},{"nctId":"NCT03317158","phase":"PHASE1, PHASE2","title":"Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder","status":"RECRUITING","sponsor":"Noah Hahn, M.D.","startDate":"2017-11-21","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":55},{"nctId":"NCT03509012","phase":"PHASE1","title":"Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-05-02","conditions":"Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma","enrollment":105},{"nctId":"NCT04989218","phase":"PHASE1, PHASE2","title":"Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2023-01-30","conditions":"Cholangiocarcinoma","enrollment":1},{"nctId":"NCT02352948","phase":"PHASE3","title":"A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-01-13","conditions":"Non - Small Cell Lung Cancer NSCLC","enrollment":597},{"nctId":"NCT02616185","phase":"PHASE1","title":"A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2015-12-30","conditions":"Prostatic Neoplasms","enrollment":91},{"nctId":"NCT03473574","phase":"PHASE2","title":"Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-05-02","conditions":"Cholangiocarcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma Non-resectable","enrollment":128},{"nctId":"NCT03472274","phase":"PHASE2","title":"Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)","status":"COMPLETED","sponsor":"Fundacion CRIS de Investigación para Vencer el Cáncer","startDate":"2018-10-25","conditions":"Bladder Cancer","enrollment":101},{"nctId":"NCT03975114","phase":"PHASE2","title":"A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2018-12-20","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":460},{"nctId":"NCT05383001","phase":"PHASE2","title":"Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)","status":"WITHDRAWN","sponsor":"AIO-Studien-gGmbH","startDate":"2022-05-20","conditions":"NSCLC Stage IV","enrollment":""},{"nctId":"NCT02658214","phase":"PHASE1","title":"Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-04-28","conditions":"Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Stomach Neoplasms","enrollment":32},{"nctId":"NCT03150836","phase":"PHASE2","title":"Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer","status":"WITHDRAWN","sponsor":"Terence Friedlander, MD","startDate":"2017-10-01","conditions":"Bladder Cancer","enrollment":""},{"nctId":"NCT00254579","phase":"PHASE2","title":"Study of CP-675,206 in Refractory Melanoma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-12","conditions":"Refractory Melanoma","enrollment":251},{"nctId":"NCT00086489","phase":"PHASE2","title":"CP-675,206 In Patients With Advanced Melanoma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-08","conditions":"Malignant Melanoma","enrollment":118}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tremelimumab (Regimen 2)","genericName":"Tremelimumab (Regimen 2)","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tremelimumab is a monoclonal antibody that blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses. Used for Unresectable or metastatic melanoma (in combination with durvalumab), Hepatocellular carcinoma (in combination with durvalumab).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}